Compare Expedia Group Inc (EXPE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Merck & Co., Inc. — how do they compare? Expedia Group Inc trades at $265.82 (market cap $32.06B), while Merck & Co., Inc. trades at $126.84 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 9.5× Expedia Group Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| EXPE | MRK | |
|---|---|---|
Market Cap | $32.06B | $305.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $129.52 |
52-Week Low | $178.06 | $77.60 |
Enterprise Value | $30.97B | $348.71B |
Dividend Yield | 0.66% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $266.28, showing modest daily gains of 0.24%. The stock exhibits a bullish technical signal, supported by strong earnings beats in recent quarters and robust revenue growth from $11.7B in 2022 to $14.7B in 2025. The company maintains high profitability with a 90.27% gross margin and recently announced a strategic partnership with Allegiant Travel Company, expanding its online travel agency network.
The investment outlook is positive with analyst consensus at $292.09, representing 9.7% upside potential. Key opportunities include continued travel sector growth and operational efficiency gains from recent technology investments. Primary risks involve macroeconomic sensitivity affecting travel demand and competitive pressures in the online travel market. The company's strong cash flow generation supports shareholder returns through dividends and potential buybacks.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
